Latest CAXTON CORP Stock Portfolio
CAXTON CORP Performance:
2025 Q3: 58.55%YTD: 37.7%2024: 60.23%
Performance for 2025 Q3 is 58.55%, and YTD is 37.7%, and 2024 is 60.23%.
About CAXTON CORP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, CAXTON CORP reported an equity portfolio of $22.9 Millions as of 30 Sep, 2025.
The top stock holdings of CAXTON CORP are RZLT, GLD, . The fund has invested 81.7% of it's portfolio in REZOLUTE INC and 11.3% of portfolio in SPDR GOLD TR.
They significantly reduced their stock positions in MIND MEDICINE MINDMED INC (MNMD). CAXTON CORP opened new stock positions in SAB BIOTHERAPEUTICS INC (SABS). The fund showed a lot of confidence in some stocks as they added substantially to SPDR GOLD TR (GLD), REZOLUTE INC (RZLT) and COMPASS THERAPEUTICS INC (CMPX).
The top stock holdings of CAXTON CORP are RZLT, GLD, . The fund has invested 81.7% of it's portfolio in REZOLUTE INC and 11.3% of portfolio in SPDR GOLD TR.
They significantly reduced their stock positions in MIND MEDICINE MINDMED INC (MNMD). CAXTON CORP opened new stock positions in SAB BIOTHERAPEUTICS INC (SABS). The fund showed a lot of confidence in some stocks as they added substantially to SPDR GOLD TR (GLD), REZOLUTE INC (RZLT) and COMPASS THERAPEUTICS INC (CMPX).
CAXTON CORP Annual Return Estimates Vs S&P 500
Our best estimate is that CAXTON CORP made a return of 58.55% in the last quarter. In trailing 12 months, it's portfolio return was 53.81%.
New Buys
| Ticker | $ Bought |
|---|---|
| sab biotherapeutics inc | 21,979 |
New stocks bought by CAXTON CORP
Additions
| Ticker | % Inc. |
|---|---|
| spdr gold tr | 47.13 |
| rezolute inc | 23.87 |
| compass therapeutics inc | 23.09 |
| berkshire hathaway inc del | 3.01 |
Additions to existing portfolio by CAXTON CORP
Reductions
| Ticker | % Reduced |
|---|---|
| mind medicine mindmed inc | -20.73 |
CAXTON CORP reduced stake in above stock
Sold off
Sector Distribution
CAXTON CORP has about 84.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 84.2 |
| Others | 15.8 |
Market Cap. Distribution
CAXTON CORP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MICRO-CAP | 82.6 |
| UNALLOCATED | 15.8 |
| SMALL-CAP | 1.4 |
Stocks belong to which Index?
About 0% of the stocks held by CAXTON CORP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 99.2 |
CAXTON CORP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of CAXTON CORP
CAXTON CORP has 12 stocks in it's portfolio. IKT proved to be the most loss making stock for the portfolio. RZLT was the most profitable stock for CAXTON CORP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| CMPX | compass therapeutics inc | 0.82 | 53,503 | 187,260 | added | 23.09 | ||
| CNTX | context therapeutics inc | 0.08 | 18,403 | 17,829 | unchanged | 0.00 | ||
| GLD | spdr gold tr | 11.33 | 7,286 | 2,589,940 | added | 47.13 | ||
| IKT | inhibikase therapeutics inc | 0.12 | 16,393 | 26,557 | unchanged | 0.00 | ||
| MNMD | mind medicine mindmed inc | 1.39 | 27,011 | 318,459 | reduced | -20.73 | ||
| RZLT | rezolute inc | 81.70 | 1,986,820 | 18,676,100 | added | 23.87 | ||
| SABS | sab biotherapeutics inc | 0.10 | 10,935 | 21,979 | new | |||
| berkshire hathaway inc del | 1.43 | 651 | 327,454 | added | 3.01 | |||
| enliven therapeutics inc | 1.17 | 13,097 | 268,106 | unchanged | 0.00 | |||
| bicara therapeutics inc | 0.76 | 10,941 | 172,760 | unchanged | 0.00 | |||
| kyverna therapeutics inc | 0.60 | 22,981 | 137,887 | unchanged | 0.00 | |||
| lexeo therapeutics inc | 0.50 | 17,332 | 115,084 | unchanged | 0.00 | |||